您的位置: 首页 > 农业专利 > 详情页

METHOD OF TREATING PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS
专利权人:
GOSUDARSTVENNOE BJUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO PROFESSIONALNOGO OBRAZOVANIJA "SEVERO-OSETINSKAJA GOSUDARSTVENNAJA MEDITSINSKAJA AKADEMIJA" MINISTERSTVA ZDRAVOOKHRANENIJA ROSSIJSKOJ F
发明人:
BURDULI NIKOLAJ MIKHAJLOVICH,Бурдули Николай Михайлович,BURDULI NINA NIKOLAEVNA,Бурдули Нина Николаевна,KULOVA LAURA ALEKSANDROVNA,Кулова Лаура Александровна
申请号:
RU2013153295
公开号:
RU2556577C1
申请日:
2013.11.29
申请国别(地区):
RU
年份:
2015
代理人:
摘要:
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used in treating patients suffering from rheumatoid arthritis. The method involves prescribing methotrexat 15 mg a week per os, folic acid 5 mg a week per os, movalis 15 mg a day per os. If the patient has the second degree of activity of rheumatoid arthritis, IL-1? of 1.3±0.3 pg/ml and more, IL-6 of 1.5±0.3 pg/ml and more, TNF-? of 1.78±0.35 pg/ml and more, IL-4 of 3.7±0.34 pg/ml and less, leptine of 6.4±0.42 pg/ml and more, glycosaminoglycans of 0.310±0.032 g/l, 7 daily procedures of intravenous laser exposure are prescribed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes. If observing the third degree of activity, IL-1? of 2.01±0.18 pg/ml and more, IL-6 of 3.01±0.38 pg/ml and more, TNF-? of 3.3±0.25 pg/ml and more, IL-4 of 1.3±0.24 pg/ml and less, leptine of 8.8±0.72 pg/ml and more, glycosaminoglycans of 1.3±0.54 g/l, 10 daily procedures are performed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5-2.0 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes.EFFECT: method enables reducing a rate of aggravations, an intensity of clinical manifestations, drug load on the patient, prolonging remissions ensured by a normalising effect on cytokine dynamics - reduced pro-inflammatory and increased anti-inflammatory cytokines.2 exИзобретение относится к медицине, а именно к ревматологии, и может быть использовано при лечении больных ревматоидным артритом. В качестве лекарственных препаратов назначают метотрексат 15 мг в неделю в
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充